Abstract
Recently, we identified in adult bone marrow (BM) a population of very small embryonic like (VSEL) stem cells (Leukemia 2006: 20;857) that arei.very small in size (∼3.5 μm),ii.CXCR4+Oct-4+ SSEA-1+Sca-1+CD45−lin−,iii.respond to SDF-1 gradient andiv.contain large nuclei with open type of euchromatin.We asked if VSEL are mobilized into peripheral blood (PB) similarly as BM-derived hematopoietic stem cells. To address this question, we evaluated VSEL level in PB afteri.pharmacological (G-CSF) andii.stress/organ damage-induced mobilization (toxic liver and skeletal muscle damage after exposure to CCl4 and cardiotoxin respectively).The number of circulating VSEL in PB was measured byi.FACS,ii.direct histochemical staining of PB-cells for SSEA-1 and Oct-4 expression, andiii.RQ-PCR analysis of pluripotent genes (Oct-4, Nanog).Finally, VSEL sorted from the PB were tested for their pluripotency in our established assay based on formation of embryoid-like spheres by VSEL in co-cultures with C2C12 cells. We report that in steady state conditions, VSEL circulate at very low levels in PB (∼100–200 cells/ml) and that the number of these cells/ml of PB is five times higher in two month old mice as compared to one year old animals. Furthermore, we found that VSEL are mobilized into PB both by G-CSF- and tissue injury and the number of circulating VSEL increases 5–6 and 2–3 times after G-CSF and after liver or skeletal muscle injury, respectively. Furthermore, the mobilization of VSEL could be additionally enhanced by blocking CXCR4 receptor by T140 antagonist. Based on this, we provide the evidence that VSELi.is a mobile pool of primitive CXCR4+SSEA-1+Oct-4+ stem cells,ii.is released into circulation during tissue/organ injury andiii.their trafficking is regulated by SDF-1-CXCR4 axis.Further studies will asses if the level of mobilized VSELi.correlates with overall regenerative potential of an organism andii.could become a helpful prognostic indicator for the clinical outcome from organ damage/injury (e.g., stroke, heart infarct).Finally, mobilized VSEL could also be employed in regenerative medicine and we are testing this possibility in appropriate animal models.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.